6.80MMarket Cap-0.32P/E (TTM)
1.1200High1.0500Low99.48KVolume1.1200Open1.1000Pre Close107.99KTurnover1.67%Turnover RatioLossP/E (Static)6.41MShares4.169952wk High1.16P/B6.32MFloat Cap0.765052wk Low--Dividend TTM5.95MShs Float236.0000Historical High--Div YieldTTM6.36%Amplitude0.7650Historical Low1.0850Avg Price1Lot Size
Adial Pharmaceuticals Stock Forum
Adial
Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Marks Final Study Needed for the Upcoming FDA Meeting for the Phase 3 Study Design and Ongoing Partnership Discussions'
GLEN ALLEN, Va., Oct. 23, 2024 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel i...
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Larger Image: tradingview.com...
$Adial Pharmaceuticals (ADIL.US)$
No comment yet